179 related articles for article (PubMed ID: 34821555)
1. The alpha/B.1.1.7 SARS-CoV-2 variant exhibits significantly higher affinity for ACE-2 and requires lower inoculation doses to cause disease in K18-hACE2 mice.
Bayarri-Olmos R; Johnsen LB; Idorn M; Reinert LS; Rosbjerg A; Vang S; Hansen CB; Helgstrand C; Bjelke JR; Bak-Thomsen T; Paludan SR; Garred P; Skjoedt MO
Elife; 2021 Nov; 10():. PubMed ID: 34821555
[TBL] [Abstract][Full Text] [Related]
2. Plant-produced SARS-CoV-2 receptor binding domain (RBD) variants showed differential binding efficiency with anti-spike specific monoclonal antibodies.
Rattanapisit K; Bulaon CJI; Khorattanakulchai N; Shanmugaraj B; Wangkanont K; Phoolcharoen W
PLoS One; 2021; 16(8):e0253574. PubMed ID: 34379620
[TBL] [Abstract][Full Text] [Related]
3. Mutations in the SARS-CoV-2 spike receptor binding domain and their delicate balance between ACE2 affinity and antibody evasion.
Xue S; Han Y; Wu F; Wang Q
Protein Cell; 2024 May; 15(6):403-418. PubMed ID: 38442025
[TBL] [Abstract][Full Text] [Related]
4. The SARS-CoV-2 Y453F mink variant displays a pronounced increase in ACE-2 affinity but does not challenge antibody neutralization.
Bayarri-Olmos R; Rosbjerg A; Johnsen LB; Helgstrand C; Bak-Thomsen T; Garred P; Skjoedt MO
J Biol Chem; 2021; 296():100536. PubMed ID: 33716040
[TBL] [Abstract][Full Text] [Related]
5. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
6. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics.
Barton MI; MacGowan SA; Kutuzov MA; Dushek O; Barton GJ; van der Merwe PA
Elife; 2021 Aug; 10():. PubMed ID: 34435953
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 B.1.1.7 (alpha) and B.1.351 (beta) variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains.
Radvak P; Kwon HJ; Kosikova M; Ortega-Rodriguez U; Xiang R; Phue JN; Shen RF; Rozzelle J; Kapoor N; Rabara T; Fairman J; Xie H
Nat Commun; 2021 Nov; 12(1):6559. PubMed ID: 34772941
[TBL] [Abstract][Full Text] [Related]
8. Possible Link between Higher Transmissibility of Alpha, Kappa and Delta Variants of SARS-CoV-2 and Increased Structural Stability of Its Spike Protein and hACE2 Affinity.
Kumar V; Singh J; Hasnain SE; Sundar D
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502041
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution.
Zahradník J; Marciano S; Shemesh M; Zoler E; Harari D; Chiaravalli J; Meyer B; Rudich Y; Li C; Marton I; Dym O; Elad N; Lewis MG; Andersen H; Gagne M; Seder RA; Douek DC; Schreiber G
Nat Microbiol; 2021 Sep; 6(9):1188-1198. PubMed ID: 34400835
[TBL] [Abstract][Full Text] [Related]
10. Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations.
Dussupt V; Sankhala RS; Mendez-Rivera L; Townsley SM; Schmidt F; Wieczorek L; Lal KG; Donofrio GC; Tran U; Jackson ND; Zaky WI; Zemil M; Tritsch SR; Chen WH; Martinez EJ; Ahmed A; Choe M; Chang WC; Hajduczki A; Jian N; Peterson CE; Rees PA; Rutkowska M; Slike BM; Selverian CN; Swafford I; Teng IT; Thomas PV; Zhou T; Smith CJ; Currier JR; Kwong PD; Rolland M; Davidson E; Doranz BJ; Mores CN; Hatziioannou T; Reiley WW; Bieniasz PD; Paquin-Proulx D; Gromowski GD; Polonis VR; Michael NL; Modjarrad K; Joyce MG; Krebs SJ
Nat Immunol; 2021 Dec; 22(12):1503-1514. PubMed ID: 34716452
[TBL] [Abstract][Full Text] [Related]
11. The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum.
Lu L; Chu AW; Zhang RR; Chan WM; Ip JD; Tsoi HW; Chen LL; Cai JP; Lung DC; Tam AR; Yau YS; Kwan MY; To WK; Tsang OT; Lee LL; Yi H; Ip TC; Poon RW; Siu GK; Mok BW; Cheng VC; Chan KH; Yuen KY; Hung IF; To KK
EBioMedicine; 2021 Sep; 71():103544. PubMed ID: 34419925
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape.
Yang L; Li J; Guo S; Hou C; Liao C; Shi L; Ma X; Jiang S; Zheng B; Fang Y; Ye L; He X
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34829998
[TBL] [Abstract][Full Text] [Related]
13. A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern
Chiem K; Morales Vasquez D; Silvas JA; Park JG; Piepenbrink MS; Sourimant J; Lin MJ; Greninger AL; Plemper RK; Torrelles JB; Walter MR; de la Torre JC; Kobie JK; Ye C; Martinez-Sobrido L
J Virol; 2021 Oct; 95(22):e0112621. PubMed ID: 34495697
[TBL] [Abstract][Full Text] [Related]
14. In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains.
Chen RE; Winkler ES; Case JB; Aziati ID; Bricker TL; Joshi A; Darling TL; Ying B; Errico JM; Shrihari S; VanBlargan LA; Xie X; Gilchuk P; Zost SJ; Droit L; Liu Z; Stumpf S; Wang D; Handley SA; Stine WB; Shi PY; Davis-Gardner ME; Suthar MS; Knight MG; Andino R; Chiu CY; Ellebedy AH; Fremont DH; Whelan SPJ; Crowe JE; Purcell L; Corti D; Boon ACM; Diamond MS
Nature; 2021 Aug; 596(7870):103-108. PubMed ID: 34153975
[TBL] [Abstract][Full Text] [Related]
15. Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species.
Wang R; Zhang Q; Ge J; Ren W; Zhang R; Lan J; Ju B; Su B; Yu F; Chen P; Liao H; Feng Y; Li X; Shi X; Zhang Z; Zhang F; Ding Q; Zhang T; Wang X; Zhang L
Immunity; 2021 Jul; 54(7):1611-1621.e5. PubMed ID: 34166623
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.
Collier DA; De Marco A; Ferreira IATM; Meng B; Datir RP; Walls AC; Kemp SA; Bassi J; Pinto D; Silacci-Fregni C; Bianchi S; Tortorici MA; Bowen J; Culap K; Jaconi S; Cameroni E; Snell G; Pizzuto MS; Pellanda AF; Garzoni C; Riva A; ; Elmer A; Kingston N; Graves B; McCoy LE; Smith KGC; Bradley JR; Temperton N; Ceron-Gutierrez L; Barcenas-Morales G; ; Harvey W; Virgin HW; Lanzavecchia A; Piccoli L; Doffinger R; Wills M; Veesler D; Corti D; Gupta RK
Nature; 2021 May; 593(7857):136-141. PubMed ID: 33706364
[TBL] [Abstract][Full Text] [Related]
17. Molecular insights into the binding interactions and energetics of the omicron spike variant with hACE2 and a neutralizing antibody.
Kumar V; Shefrin S; Sundar D
J Struct Biol; 2024 Jun; 216(2):108087. PubMed ID: 38494148
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern.
Kovacech B; Fialova L; Filipcik P; Skrabana R; Zilkova M; Paulenka-Ivanovova N; Kovac A; Palova D; Rolkova GP; Tomkova K; Csokova NT; Markova K; Skrabanova M; Sinska K; Basheer N; Majerova P; Hanes J; Parrak V; Prcina M; Cehlar O; Cente M; Piestansky J; Fresser M; Novak M; Slavikova M; Borsova K; Cabanova V; Brejova B; Vinař T; Nosek J; Klempa B; Eyer L; Hönig V; Palus M; Ruzek D; Vyhlidalova T; Strakova P; Mrazkova B; Zudova D; Koubkova G; Novosadova V; Prochazka J; Sedlacek R; Zilka N; Kontsekova E
EBioMedicine; 2022 Feb; 76():103818. PubMed ID: 35078012
[TBL] [Abstract][Full Text] [Related]
19. Functional Effects of Receptor-Binding Domain Mutations of SARS-CoV-2 B.1.351 and P.1 Variants.
Bayarri-Olmos R; Jarlhelt I; Johnsen LB; Hansen CB; Helgstrand C; Rose Bjelke J; Matthiesen F; Nielsen SD; Iversen KK; Ostrowski SR; Bundgaard H; Frikke-Schmidt R; Garred P; Skjoedt MO
Front Immunol; 2021; 12():757197. PubMed ID: 34691078
[TBL] [Abstract][Full Text] [Related]
20. E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies.
Wang WB; Liang Y; Jin YQ; Zhang J; Su JG; Li QM
J Mol Graph Model; 2021 Dec; 109():108035. PubMed ID: 34562851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]